U.S. Markets open in 1 hr 26 mins

Hemispherx Biopharma, Inc. Discusses Clinical Development and Competitive Advantage in New SNNLive Video Interview on StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / July 2, 2019 / StockNewsNow.com, The Official MicroCap News Source, today published an SNNLive Video Interview with Thomas Equels, CEO of Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, according to the company's website (see here: www.hemispherx.net). The video interview was recorded at the Planet MicroCap Showcase 2019 in Las Vegas, NV.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Update with Hemispherx Biopharma, Inc. - Specialty Pharmaceutical Company Discusses Clinical Development and Competitive Advantage

Hemispherx recently released its second quarterly update for its Ampligen in Immuno-Oncology program.

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

For more information about Hemispherx Biopharma, Inc., please visit: www.hemispherx.net

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

CONTACT:

StockNewsNow.com
info@snnwire.com

SOURCE: StockNewsNow.com



View source version on accesswire.com:
https://www.accesswire.com/550584/Hemispherx-Biopharma-Inc-Discusses-Clinical-Development-and-Competitive-Advantage-in-New-SNNLive-Video-Interview-on-StockNewsNowcom